# A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer

> **NCT04380103** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 106 (estimated)

## Conditions studied

- Metastatic Cancer
- Colorectal Cancer
- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** XELOXIRI/Bevacizumab

## Key facts

- **NCT ID:** NCT04380103
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-26
- **Primary completion:** 2020-12
- **Final completion:** 2022-09
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2020-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04380103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04380103, "A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04380103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*